Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Nov;79(11):1475-1503.
doi: 10.1007/s00228-023-03556-7. Epub 2023 Aug 30.

Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies

Shaodi Ma #  1 , Weihang Xia #  1 , Birong Wu #  1 , Chenyu Sun  2   3 , Yuemeng Jiang  4 , Haixia Liu  1 , Scott Lowe  5 , Zhen Zhou  6 , Peng Xie  1 , Juan Gao  1 , Linya Feng  1 , Xianwei Guo  1 , Guangbo Qu  1 , Yehuan Sun  7   8   9
Affiliations
Meta-Analysis

Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies

Shaodi Ma et al. Eur J Clin Pharmacol. 2023 Nov.

Abstract

Purpose: Aspirin has been suggested to reduce the risk of cancer. However, previous studies have been inconsistent regarding the relationship between aspirin use and the risk of occurrence of prostate cancer (PCa). The purpose of this study was to assess the effect of aspirin on clinical outcomes in patients with PCa in a meta-analysis and to explore the possible dose-response relationship.

Methods: A systematic literature search was conducted in 10 electronic databases and 4 registries. The combined relative risks (RRs) were calculated using a random-effects model with 95% confidence interval (CIs) to assess the effect of aspirin on the risk of PCa. Relevant subgroup analyses and sensitivity analyses were performed.

Results: The across studies results show that aspirin use associated with lower incidence of PCa (RR: 0.96, 95% CI: 0.95-0.98), and reduced mortality (RR: 0.88, 95% CI: 0.82-0.95). The results of the subgroup analysis indicated that both cohort and population studies in the Americas showed a reduction in PCa incidence and mortality with aspirin use. A linear correlation was observed between dosage/duration of aspirin use and its protective effect. Additionally, post-diagnosis aspirin use was associated with decreased risk of PCa mortality.

Conclusions: This meta-analysis revealed an independent correlation between the use of aspirin and reductions in both the incidence and mortality rates of PCa. However, randomized controlled trials did not find any association between aspirin use and PCa. Furthermore, the impact of aspirin on PCa occurrence was found to be dependent on both dosage and duration.

Keywords: Aspirin; Dose-response relationship; Meta-analysis; Prostate cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(4):524–548. https://doi.org/10.1001/jamaoncol.2016.5688 - DOI - PMC
    1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
    1. de Bono JS, Guo C, Gurel B et al (2020) Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer 20(8):455–469. https://doi.org/10.1038/s41568-020-0267-9 - DOI - PubMed
    1. Lin M, Sun X, Lv L (2023) New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer. Mol Ther Oncolytics 29:91–106. https://doi.org/10.1016/j.omto.2023.04.007 - DOI - PubMed - PMC
    1. Zhang YH, Chen XL, Wang YR et al (2023) Prevention of malignant digestive system tumors should focus on the control of chronic inflammation. World J Gastrointest Oncol 15(3):389–404. https://doi.org/10.4251/wjgo.v15.i3.389 - DOI - PubMed - PMC

Publication types

LinkOut - more resources